Abstract:Kuo-Tung Hung, 1 Shih-Cheng Yang, 1 Cheng-Kun Wu, 1, 2 Hsing-Ming Wang, 1 Chih-Chien Yao, 1 Chih-Ming Liang, 1, 2 Wei-Chen Tai, 1, 2 Keng-Liang Wu, 1, 2 Yuan-Hung Kuo, 1, 2 Chen-Hsiang Lee, 2, 3 Seng-Kee Chuah 1, 2 1 Division of Hepatogastroenterology, Department of Internal Medicine, Chang Gung Memorial Hospital, Kaohsiung, Taiwan; 2 Chang Gung University, College of Medicine, Taoyuan, Taiwan; 3 Division of Infectious Disease, Department of Internal Medicine, Chang Gung Memorial Hospital, Kaohsiung, Taiwan Correspondence: Seng-Kee Chuah; Chih-Ming Liang Division of Hepatogastroenterology, Chang Gung Memorial Hospital, 123, Ta-Pei Road, Niao-Sung Hsiang, Kaohsiung, 833, Taiwan Tel + 886-7-7317123 ext. 8301 Fax + 886-7-7322402 Email chuahsk@seed.net.tw; gimy54861439@gmail.com Purpose: Non-bismuth concomitant quadruple therapy is commonly administered in Taiwan, achieving an acceptable efficacy as a first-line anti -Helicobacter pylori treatment. This study compared the eradication rates between esomeprazole- and lansoprazole-based non-bismuth concomitant quadruple therapy for first-line anti- H. pylori treatment. Patients and Methods: This study included 206 H. pylori -infected naïve patients between July 2016 and February 2019. The patients were prescribed with either a 7-day non-bismuth containing quadruple therapy (esomeprazole, 40 mg twice daily; amoxicillin, 1 g twice daily; and metronidazole, 500 mg twice daily; and clarithromycin, 500 mg twice daily for 7 days [EACM group]; lansoprazole, 30 mg twice daily; amoxicillin, 1 g twice daily; metronidazole, 500 mg twice daily; and clarithromycin, 500 mg twice daily [LACM group]). Then, the patients were asked to perform urea breath tests 8 weeks later. Results: The eradication rates in the EACM group were 86.1% (95% confidence interval [CI], 77.8%– 92.2%) and 90.6% (95% CI, 82.9%– 95.6%) in the intention-to-treat (ITT) and the per-protocol (PP) analyses, respectively. Moreover, the eradication rates in the LACM group were 90.1% (95% CI, 82.6%– 95.2%) and 92.6% (95% CI, 85.5%– 96.9%) in the ITT and the PP analyses, respectively. Consequently, the LACM group exhibited more diarrhea patients than the EACM group (7.1% versus 1.0%, p = 0.029), but all symptoms were mild. Univariate analysis in this study showed that metronidazole-resistant strains were the clinical factor affecting the eradications (95.3% versus 78.9%, p = 0.044). Moreover, a trend was observed in dual clarithromycin- and metronidazole-resistant strains (91.5% versus 66.7%, p = 0.155). Conclusion: The eradication rates between esomeprazole and lansoprazole-based non-bismuth concomitant quadruple therapy for first-line H. pylori treatment were similar in this study. Both could achieve a > 90% report card in the PP analysis. Keywords: Helicobacter pylori , esomeprazole, lansoprazole, concomitant therapy, antibiotic resistance

Comparison of Two Low_dose Short_term Triple Therapies for Eradication of Helicobacter Pylori Infection

Long-term Therapeutic Effect of Triple Therapy Consisted of Omeperazole,clarithromycin and Amoxycillin in Children with Helicobacter Pylori Infection and Approach to Re-Treatment after Failure of the Treatment

Is Short-Term Therapy Really Sufficient to Eradicate Helicobacter Pylori Infection?

Efficacy of quadruple therapy with clarithromycin based on faecal molecular antimicrobial susceptibility tests as first-line treatment for <i>Helicobacter pylori</i> infection: a protocol of a single-centre, single-blind, randomised clinical trial in China

Comparative Effectiveness And Tolerance Of Treatments For Helicobacter Pylori: Systematic Review And Network Meta-Analysis

Non-bismuth Quadruple Therapy Versus Standard Triple Therapy for Helicobacter Pylori Eradication: a Randomized Controlled Study

Comparison of efficacy of different treatment regimens on H.Pylori Eradication

Efficacy of Triple Therapy and Sequential Therapy in the Eradication of Helicobacter Pylori in Patients Receiving Long-Term Non-Steroidal Anti-Inflammatory Drugs Treatment

Efficacy of Tetracycline-containing Triple Therapy for Eradication of Helicobacter pylori Infection

A Comparative Study of 14‐day Dual Therapy (esomeprazole and Amoxicillin Four Times Daily) and Triple Plus Bismuth Therapy for First‐line Helicobacter Pylori Infection Eradication: A Randomized Trial

Meta-analysis of Esomeprazole-Based Triple Therapies in Helicobacter Pylori Eradication

A randomized clinical study on the efficacy of vonoprazan combined with amoxicillin duo regimen for the eradication of Helicobacter pylori

Comparative Study on Eradication Therapy of 1 440 Newly Diagnosed Patients with Helicobacter Pylori Infection

Comparison of ranitidine bismuth citrate and lansoprazole-based regimens in the treatment of Helicobacter pylori infection

Different Duration of Quadruple Therapy for First-line Helicobacter Pylori Eradication Treatment——A Randomized,Controlled Trial

A Multicentre Study on Eradication of Helicobacter Pylori Using Four 1-Week Triple Therapies in China.

Eradication Rates for Esomeprazole and Lansoprazole-Based 7-Day Non-Bismuth Concomitant Quadruple Therapy for First-Line Anti-Helicobacter pylori Treatment in Real World Clinical Practice

Efficacy of PPI-based Standard Triple Therapy Combined with Teprenone for Treatment of Helicobacter pylori Infection

Comparison of vonoprazan bismuth‐containing triple therapy with quadruple therapy in Helicobacter pylori‐infected treatment‐naive patients: a prospective multicenter randomized controlled trial

Comparing high-dose dual therapy with bismuth-containing quadruple therapy for the initial eradication of Helicobacter pylori infection on Hainan Island: a randomized, multicenter clinical trial

Eradication Of H Pylori Infection In A Rural Population: One-Day Quadruple Therapy Versus 7-Day Triple Therapy